Back to Search Start Over

Impact of respiratory viral infections on mortality and critical illness among hospitalized patients with chronic obstructive pulmonary disease.

Authors :
Mulpuru, Sunita
Andrew, Melissa K.
Ye, Lingyun
Hatchette, Todd
LeBlanc, Jason
El‐Sherif, May
MacKinnon‐Cameron, Donna
Aaron, Shawn D.
Alvarez, Gonzalo G.
Forster, Alan J.
Ambrose, Ardith
McNeil, Shelly A.
Source :
Influenza & Other Respiratory Viruses; Nov2022, Vol. 16 Issue 6, p1172-1182, 11p
Publication Year :
2022

Abstract

Background: Seasonal respiratory viral infections are associated with exacerbations and morbidity among patients with COPD. The real‐world clinical outcomes associated with seasonal viral infections are less well established among hospitalized patients. Research Question: To estimate the association between seasonal respiratory viral infections, 30‐day mortality, and intensive care unit (ICU) admission among hospitalized COPD patients. Study Design and Methods: We conducted an analysis of a national prospective multicenter cohort of COPD patients hospitalized with acute respiratory illness during winter seasons (2011–2015) in Canada. Nasopharyngeal swabs were performed on all patients at the onset of hospital admission for diagnosis of viral infection. Primary outcomes were 30‐day mortality and ICU admissions. Secondary outcomes included invasive/non‐invasive ventilation use. Results: Among 3931 hospitalized patients with COPD, 28.5% (1122/3931) were diagnosed with seasonal respiratory viral infection. Viral infection was associated with increased admission to ICU (OR 1.5, 95% CI 1.2–1.9) and need for mechanical ventilation (OR 1.9, 95% CI 1.4–2.5), but was not associated with mortality (OR 1.1, 95% CI 0.8–1.4). Patients with respiratory syncytial virus (RSV) were equally likely to require ICU admission (OR 1.09, 95% CI 0.67–1.78), and more likely to need non‐invasive ventilation (OR 3.1; 95% CI 1.8–5.1) compared to patients with influenza. Interpretation: Our results suggest COPD patients requiring hospitalization for respiratory symptoms should routinely receive viral testing at admission, especially for RSV and influenza, to inform prognosis, clinical management, and infection control practices during winter seasons. Patients with COPD will be an important target population for newly developed RSV therapeutics. Clinical Trial Registration: ClinicalTrials.gov ID: NCT01517191. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17502640
Volume :
16
Issue :
6
Database :
Complementary Index
Journal :
Influenza & Other Respiratory Viruses
Publication Type :
Academic Journal
Accession number :
159504237
Full Text :
https://doi.org/10.1111/irv.13050